| Beth E Nelson, MD | |
|
1000 Asylum Ave, Ste 2110, Hartford, CT 06105-1719 | |
| (860) 714-7945 | |
| (860) 714-8880 |
| Full Name | Beth E Nelson |
|---|---|
| Gender | Female |
| Speciality | Obstetrics & Gynecology - Gynecologic Oncology |
| Location | 1000 Asylum Ave, Hartford, Connecticut |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1093711954 | NPI | - | NPPES |
| 00129762 | Medicaid | CT |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207VX0201X | Obstetrics & Gynecology - Gynecologic Oncology | 029762 (Connecticut) | Primary |
| Entity Name | Trinity Health Of New England Provider Network Organization Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1003882812 PECOS PAC ID: 0941113567 Enrollment ID: O20031110000651 |
News Archive
An experimental tuberculosis drug may be effective against not only multi drug-resistant forms of the disease but could also be the first compound to treat the latent stage of infection as well. Researchers reported their results at the 2006 ASM Biodefense Research Meeting.
Suicide Awareness Voices of Education (SAVE) hosted a Suicide Survivor and Bereavement Leadership Summit, which brought together 20 of the nation's leading caregivers, researchers, and pioneers in the field of suicide grief support to discuss how to better help people bereaved by suicide in communities across the United States.
Regulus Therapeutics Inc. today announced the publication of new results in the journal Nature Biotechnology by Regulus scientists and collaborators. The new study demonstrated that systemic treatment of a microRNA therapeutic targeting microRNA-10b in tumor-bearing mice inhibits breast cancer metastasis. Cancer-related metastasis is a major cause of mortality and current cancer treatments have limited utility suppressing the metastatic spread of cancer cells. microRNA therapeutics targeting miR-10b represent a promising approach for the discovery and development of a novel anti-metastatic agent.
It has been "difficult over the years to get a good statistical handle on the size of the AIDS problem in this country," a New York Times editorial says, adding, "But by the latest and most sophisticated measurements, the disease continues to frustrate federal and local efforts to rein it in."
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Beth E Nelson, MD 1000 Asylum Ave, Ste 2110, Hartford, CT 06105-1719 Ph: (860) 714-7945 | Beth E Nelson, MD 1000 Asylum Ave, Ste 2110, Hartford, CT 06105-1719 Ph: (860) 714-7945 |
News Archive
An experimental tuberculosis drug may be effective against not only multi drug-resistant forms of the disease but could also be the first compound to treat the latent stage of infection as well. Researchers reported their results at the 2006 ASM Biodefense Research Meeting.
Suicide Awareness Voices of Education (SAVE) hosted a Suicide Survivor and Bereavement Leadership Summit, which brought together 20 of the nation's leading caregivers, researchers, and pioneers in the field of suicide grief support to discuss how to better help people bereaved by suicide in communities across the United States.
Regulus Therapeutics Inc. today announced the publication of new results in the journal Nature Biotechnology by Regulus scientists and collaborators. The new study demonstrated that systemic treatment of a microRNA therapeutic targeting microRNA-10b in tumor-bearing mice inhibits breast cancer metastasis. Cancer-related metastasis is a major cause of mortality and current cancer treatments have limited utility suppressing the metastatic spread of cancer cells. microRNA therapeutics targeting miR-10b represent a promising approach for the discovery and development of a novel anti-metastatic agent.
It has been "difficult over the years to get a good statistical handle on the size of the AIDS problem in this country," a New York Times editorial says, adding, "But by the latest and most sophisticated measurements, the disease continues to frustrate federal and local efforts to rein it in."
› Verified 1 days ago
Ellen Robinson, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 100 Retreat Ave, Suite 201, Hartford, CT 06106 Phone: 860-246-8568 Fax: 860-728-5076 | |
Howard Andrew Shaw, MD, MBA Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 1000 Asylum Ave, Suite 2110, Hartford, CT 06105 Phone: 860-714-7945 Fax: 860-714-8880 | |
Mark Wolf, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 1000 Asylum Ave, Suite 4319, Hartford, CT 06105 Phone: 860-714-4440 Fax: 860-714-8012 | |
Behzad Satvat, MD Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 136 Retreat Ave, Hartford, CT 06106 Phone: 860-547-0306 Fax: 860-525-9782 | |
Felice Colliton, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 19 Woodland Street, Suite 31, Hartford, CT 06105 Phone: 860-728-1212 Fax: 860-724-5224 | |
Elena Tunitsky-bitton, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 80 Seymour Street, Hartford Hospital Professional Services, Hartford, CT 06102 Phone: 860-545-4338 | |
Dr. Charles J. Ingardia, M.D. Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 80 Seymour Street, Hartford Hospital Maternal-fetal Medicine, Hartford, CT 06102 Phone: 860-545-2884 |